This page shows the latest Intarcia news and features for those working in and with pharma, biotech and healthcare.
New injection-less therapy could revolutionise diabetes treatment. Biopharmaceutical company Intarcia Therapeutics' novel sub-dermal pump ITCA 650 has significantly outperformed Januvia in phase III trials. . ... Kurt Graves, chairman, president and CEO
Tiny pump implant to deliver GLP-1 agonist. Intarcia's ITCA 650 pump implant is the size of a matchstick. ... Intarcia retains rights to the implant in the US and says it is in the process of seeking a licensee in Japan.
and interferon ω (Intarcia Therapeutics).
More from news
Approximately 2 fully matching, plus 1 partially matching documents found.
Moves to the Boston company from Onyx Pharmaceuticals. Boston-based biopharmaceutical firm Intarcia Therapeutics has appointed Dr Sunita Zalani as vice president, global head of regulatory affairs and quality. ... He said: "We led a very competitive
More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.
We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...